Pharmaceutical patents and price controls

Clinical Therapeutics

Volumn 24, Issue 7, 2002, Pages 1204-1222

  Vogel, Ronald J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cost shifting; Patents; Pharmaceutical R D; Price controls

Indexed keywords

COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESEARCH; ECONOMIC ASPECT; GOVERNMENT; HUMAN; MODEL; PATENT; PROSPECTIVE PRICING; REVIEW; ARTICLE; COMMERCIAL PHENOMENA; ECONOMICS; LEGAL ASPECT; RESEARCH;

COMMERCE; DRUG INDUSTRY; HUMANS; PATENTS; RESEARCH;

EID: 0036331721     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80031-5     Document Type: Note

References (24)

1. Why drugs cost so much
2. Returns to R&D on new drug introductions in the 1980s
3. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade
4. Intellectual property protection for pharmaceuticals: Emerging issues in a global economy
5. The pharmaceutical development process: Estimates of development costs and times and the effects of proposed regulatory changes
6. A contribution to the theory of taxation
7. The pharmaceutical industry - To whom is it accountable?
8. High drug prices: For research or profit
9. The potential unintended economic consequences of the Medicine Equity and Drug Safety Act of 2000